The Emirates Drug Establishment (EDE) issued Circular No. 40/2026 on 11 September 2026 regarding unauthorized medical products marketed as containing Exosomes and/or Polydeoxyribonucleotide (PDRN).
The regulatory warning is particularly relevant to manufacturers, brand owners, distributors, healthcare facilities and professionals operating in the regenerative medicine and aesthetic sectors.
According to the circular, EDE has identified unauthorized products being circulated or used for cosmetic, regenerative or therapeutic purposes, including administration by injection, mesotherapy, Dermapen, microneedling and other invasive medical procedures.
EDE states that the products covered by the circular are not authorized for importation, supply, sale, distribution or clinical use in the UAE.
Why does this matter?
For unauthorized products, important characteristics such as identity, source, composition, concentration, quality, sterility, purity, stability, effectiveness and safety may not have been adequately established through the UAE regulatory process.
Potential risks identified by EDE include contamination and infection, allergic or inflammatory reactions, injection or procedure-site complications, inconsistent quality controls, unsupported therapeutic or cosmetic claims and uncertain long-term risks.
The circular also calls for regulatory controls covering healthcare facilities, pharmaceutical establishments, importation, customs clearance, courier shipments and e-commerce orders.
What should manufacturers and brand owners do?
The key question should not simply be: “Can we sell this product in the UAE?”
The correct starting point is: “How will this product be classified in the UAE, and what EDE authorization does it require?”
Companies considering the UAE market for Exosome, PDRN, regenerative, aesthetic or other innovative medical products should establish the regulatory pathway before shipment or commercialization.
A structured approach should include:
- Product Classification
- Regulatory Pathway Assessment
- Manufacturer / MAH requirements
- Technical dossier and evidence assessment
- EDE Marketing Authorization, where required
- Compliant importation and commercialization
- Post-authorization lifecycle compliance
EDE Product Classification
EDE provides an official Product Classification service to determine the regulatory category of a product based on factors including its presentation, composition, intended use and design.
The resulting classification determines the applicable UAE regulatory framework and whether EDE Marketing Authorization is required.
Where Marketing Authorization is required, the product should proceed through the appropriate EDE registration pathway before being placed on the UAE market.
Regulatory authorization before commercialization
For innovative products, regulatory strategy should begin before commercial shipment, distribution arrangements, promotional activities or clinical use.
Early regulatory assessment can help manufacturers identify classification issues, dossier gaps, manufacturer and MAH requirements, evidence requirements, artwork and labeling requirements and the appropriate UAE market-entry pathway.
How ViaFarma Solutions can support you
ViaFarma Solutions supports international manufacturers and brand owners throughout the UAE regulatory and market-entry process, including:
- UAE regulatory pathway assessment
- EDE Product Classification support
- Manufacturer and MAH registration coordination
- Technical dossier and regulatory gap assessment
- EDE Marketing Authorization / product registration support
- Artwork and labeling compliance
- Variations and renewals
- Regulatory lifecycle management
- Market-entry and commercialization coordination
If your company manufactures Exosome, PDRN, regenerative medicine, aesthetic medicine or other innovative healthcare products and is considering entering the UAE market, establish the regulatory pathway before shipment or commercialization.
